Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoride Gel for White Spot Lesions
NCT01329731Phase 4Completed
- Sponsor
- GABA Therapeutics
- Start
- Mar 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Elmex Gelée in White spot lesion (WSL) (2 arms), sponsored by GABA Therapeutics. Primary endpoint: White Spot Lesion size change at 12 weeks. Started Mar 2011; status: completed.
02
Drugs
Elmex Gelée
03
Conditions
White spot lesion (WSL)
Beyond the preview
Go deeper on NCT01329731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329731.